The present invention provides novel anti-glycating peptide against diabetes. Certain aspects of the invention includes designing of novel peptide via in-silico approaches, which are further used to inhibit the glycation of proteins, in particular, the glycation of Human Serum Albumin. Thereafter, the peptide was checked for the in-vitro as well as in-vivo anti-diabetic potential using a-amylase inhibition and a-glucosidase inhibition assay showing IC50 value upto 0.090 and 0.097mM, respectively.
